Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NU172 in Off-Pump CABG Surgery
NCT00808964Phase 2Unknown
- Sponsor
- Oruka Therapeutics
- Start
- Jan 2013
- Primary completion
- Jun 2013
- Modality
- RNA Aptamers, DNA Aptamers
01
Overview
Phase 2, open-label, single-arm trial of NU172 in thrombosis, sponsored by Oruka Therapeutics. Primary endpoint: Safety and efficacy of NU172 in patients undergoing off-pump CABG surgery at 30 days. Status: unknown.
02
Drugs
NU172
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT00808964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00808964.